`
`CONFORMIS, INC.,
`
`
`UNITED STATES DISTRICT COURT
`MIDDLE DISTRICT OF FLORIDA
`TAMPA DIVISION
`
`
`
`
`
`
`Civil Action No.:
`
`
`
`
`
`
`Plaintiff,
`
`
`v.
`
`EXACTECH, INC.
`
`
`Defendant.
`
`
`COMPLAINT FOR PATENT INFRINGEMENT, PERMANENT
`INJUNCTIVE RELIEF REQUESTED,
`AND DEMAND FOR A JURY TRIAL
`
`
`Plaintiff Conformis, Inc. (“Conformis”), for its Complaint and demand for a
`
`jury trial seeking relief for patent infringement against Defendant Exactech, Inc.
`
`(“Exactech” or “Defendant”), states and alleges as follows:
`
`I.
`
`THE PARTIES
`
`1.
`
`Plaintiff Conformis, Inc. is incorporated in Delaware with its
`
`worldwide headquarters at 600 Technology Park Drive, Billerica, Massachusetts,
`
`01730.
`
`2.
`
`On information and belief, Defendant Exactech, Inc. is a corporation
`
`organized under the laws of the State of Florida, and maintains a place of business
`
`at 1189 Tallevast Road, Sarasota, Florida 34243.
`
`1
`
`
`
`Case 8:21-cv-01348-KKM-TGW Document 1 Filed 06/03/21 Page 2 of 22 PageID 2
`
`II.
`
`JURISDICTION AND VENUE
`
`3.
`
`This Court has subject-matter jurisdiction over Conformis’s claims
`
`under 28 U.S.C. §§ 1331 and 1338(a) because these claims arise under the patent
`
`laws of the United States, 35 U.S.C. § 1, et seq.
`
`4.
`
`Exactech is subject to this Court’s general and specific personal
`
`jurisdiction at least because: Exactech is at home in the State of Florida where it is
`
`incorporated; Exactech has registered agents for service of process in Florida,
`
`regularly conducts business in the State of Florida and within this judicial district,
`
`and has substantial and continuous contacts within this judicial district; Exactech
`
`has purposefully availed itself of the privileges of conducting business in this
`
`judicial district and has a regular and established place of business in this judicial
`
`district; and Exactech has committed acts of patent infringement in this judicial
`
`district by selling and offering to sell products and services throughout the United
`
`States, including in this judicial district, and introducing infringing products and
`
`services into the stream of commerce knowing that they would be sold in this
`
`judicial district and elsewhere in the United States.
`
`5.
`
`Venue in this Court is proper under the provisions of 28 U.S.C.
`
`§§ 1391(b)–(c) and 1400.
`
`III. THE ASSERTED PATENTS
`
`6.
`
`Conformis has developed significant intellectual property associated
`
`with its iFit® technology, its patient-specific implants, and its iJig® patient-
`2
`
`
`
`Case 8:21-cv-01348-KKM-TGW Document 1 Filed 06/03/21 Page 3 of 22 PageID 3
`
`specific instruments, including a large portfolio of patents and pending patent
`
`applications. These patents and patent applications span a range of related
`
`technologies including imaging software, image processing, patient-specific
`
`orthopedic implants, patient-specific orthopedic instrumentation, methods of
`
`design and manufacture of patient-specific System, and related surgical techniques.
`
`The technology covered by this patent portfolio is applicable to major joint
`
`systems, including knee, hip, shoulder, and ankle joints.
`
`7.
`
`Patent authorities worldwide have recognized that Conformis’s
`
`patient-specific instrument systems are worthy of patent protection and have
`
`granted Conformis over 200 patents on its technologies. The United States Patent
`
`and Trademark Office (“USPTO”) awarded a robust patent portfolio that protects
`
`Conformis’s inventions relating to its iFit® technology, its patient-specific
`
`implants, and its iJig® patient-specific instruments, including:
`
`8.
`
`On June 11, 2013, the U.S. Patent and Trademark Office duly and
`
`legally issued U.S. Patent No. 8,460,304 (“the ’304 Patent”), entitled “Joint
`
`Arthroplasty Devices and Surgical Tools,” to Wolfgang Fitz, Philipp Lang, Daniel
`
`Steines, Konstantinos Tsougarakis, and Rene Vargas-Voracek. Conformis is the
`
`owner by assignment of the ’304 Patent. A copy of the ’304 Patent is attached
`
`hereto as Exhibit A.
`
`9.
`
`On March 29, 2016, the U.S. Patent and Trademark Office duly and
`
`legally issued U.S. Patent No. 9,295,482 (“the ’482 Patent”), entitled “Patient
`3
`
`
`
`Case 8:21-cv-01348-KKM-TGW Document 1 Filed 06/03/21 Page 4 of 22 PageID 4
`
`Selectable Joint Arthroplasty Devices and Surgical Tools,” to Wolfgang Fitz,
`
`Philipp Lang, Raymond Bojarski, and Daniel Steines. Conformis is the owner by
`
`assignment of the ’482 Patent. A copy of the ’482 Patent is attached hereto as
`
`Exhibit B.
`
`10. On January 7, 2014, the U.S. Patent and Trademark Office duly and
`
`legally issued U.S. Patent No. 8,623,026 (“the ’026 Patent”), entitled “Patient
`
`Selectable Joint Arthroplasty Devices and Surgical Tools Incorporating Surgical
`
`Relief,” to Terrence Wong, Raymond Bojarski, Daniel Steines, and Philipp Lang.
`
`Conformis is the owner by assignment of the ’026 Patent. A copy of the ’026
`
`Patent is attached hereto as Exhibit C.
`
`11. On May 3, 2016, the U.S. Patent and Trademark Office duly and
`
`legally issued U.S. Patent No. 9,326,780 (“the ’780 Patent”), entitled “Patient
`
`Selectable Joint Arthroplasty Devices and Surgical Tools Incorporating
`
`Anatomical Relief,” to Terrence Wong, Raymond Bojarski, Daniel Steines, and
`
`Philipp Lang. Conformis is the owner by assignment of the ’780 Patent. A copy
`
`of the ’780 Patent is attached hereto as Exhibit D.
`
`12. On November 17, 2015, the U.S. Patent and Trademark Office duly
`
`and legally issued U.S. Patent No. 9,186,161 (“the ’161 Patent”), entitled “Surgical
`
`Tools for Arthroplasty,” to Philipp Lang, Wolfgang Fitz, Ray Bojarski, Daniel
`
`Steines, Albert G. Burdulis, Jr., and Rene Vargas-Voracek. Conformis is the
`
`4
`
`
`
`Case 8:21-cv-01348-KKM-TGW Document 1 Filed 06/03/21 Page 5 of 22 PageID 5
`
`owner by assignment of the ’161 Patent. A copy of the ’161 Patent is attached
`
`hereto as Exhibit E.
`
`13. Collectively, the ’304, ’482, ’026, ’780, and ’161 Patents are the
`
`“Asserted Patents.”
`
`14. This is an action for infringement of the Asserted Patents.
`
`IV. FACTUAL BACKGROUND
`
`Conformis’s Revolutionary Technology
`
`15. Conformis is the world’s leading designer, developer, and
`
`manufacturer of patient-specific knee and hip implants and the surgical tools to fit
`
`those implants into a specific patient’s body. Founded by doctors affiliated with
`
`Stanford and Harvard Medical Schools, Conformis began with a revolutionary
`
`idea: make the implant fit the patient rather than forcing the patient to fit the
`
`implant.
`
`16. For decades before Conformis’s innovation—and continuing today—
`
`implant manufacturers offered surgeons a standard set of implant sizes, akin to the
`
`small-medium-large sizing in off-the-rack department stores. This approach forces
`
`the surgeon to pick an implant size that appears closest in fit to the patient’s
`
`anatomy but is not designed for and does not truly fit each individual patient. The
`
`surgeon must therefore make size, shape, and other compromises to fit the implant
`
`as best as possible.
`
`5
`
`
`
`Case 8:21-cv-01348-KKM-TGW Document 1 Filed 06/03/21 Page 6 of 22 PageID 6
`
`17. These blunt efforts are further hampered by using standard tools to
`
`implant standard implants, none of which are designed using an individual
`
`patient’s anatomy. Because of this imprecise approach, patients often suffer loss
`
`of movement and function, instability, and lingering pain after surgery.
`
`18. Conformis recognized that the conventional joint-repair process was
`
`backwards: rather than fitting the patient to the implant, the implant should be
`
`designed and developed specifically for the patient. This produces a better-fitting
`
`implant with a shape that feels more natural to the patient because patients vary
`
`physiologically in the size, dimensions, shape, position, orientation, and range of
`
`motion of their joints.
`
`19. Conformis therefore set out to develop its proprietary iFit®
`
`technology to create both patient-specific implants and instruments. Conformis
`
`implants are individually sized and shaped to fit each patient’s unique anatomy,
`
`providing a precise anatomic fit and better preserving healthy tissue while leading
`
`to increased function and a more natural feel. The patient-specific instrument
`
`systems of Conformis—which use Conformis’s iJig® technology—precisely place
`
`the patient-specific implant, reduce surgical time and trauma, and create a
`
`reproducible surgical technique. Conformis iJigs® eliminate many of the
`
`traditional instruments associated with conventional surgery while concurrently
`
`simplifying and improving the surgical technique.
`
`6
`
`
`
`Case 8:21-cv-01348-KKM-TGW Document 1 Filed 06/03/21 Page 7 of 22 PageID 7
`
`20. By combining personalized implants with patient-specific
`
`instrumentation, a surgeon can provide treatment that: a) is tailored to the patient;
`
`b) preserves more of the patient’s joint; and c) minimizes surgical trauma. These
`
`patient-specific implant systems fit and work with the individual patient’s
`
`anatomy.
`
`21. Conformis’s patient-specific implant systems are recognized around
`
`the world. The U.S. Food and Drug Administration has approved knee and hip
`
`implant systems by Conformis for use in the United States. The European Union
`
`has approved Conformis’s knee-implant systems for use in Europe. And
`
`Conformis currently sells a full line of patient-specific knee- and hip-implant
`
`systems in many countries worldwide. To date, Conformis’s patient-specific
`
`implants and customized tools have helped improve the lives of thousands of
`
`Americans.
`
`Exactech’s Infringing Activities
`
`22. Exactech offers a line of patient-specific surgical systems and
`
`proprietary software that allows surgeons to customize ankle-implant surgery
`
`according to a patient’s unique anatomy that includes patient-specific instruments
`
`(“PSI”) for use with its ankle implants (the “Accused System”). See generally Exs.
`
`K-T.
`
`23. On March 10, 2016, the Food and Drug Administration (FDA)
`
`provided 510(k) clearance for the Vantage® Total Ankle System under the Device
`7
`
`
`
`Case 8:21-cv-01348-KKM-TGW Document 1 Filed 06/03/21 Page 8 of 22 PageID 8
`
`Classification Name: “Prosthesis, Ankle, Semi-Constrained, Cemented,
`
`Metal/Polymer.” Ex. T at 1. On November 09, 2020, the FDA provided 510(k)
`
`clearance for the Vantage® Ankle PSI under the Device Classification Name:
`
`“Ankle Arthroplasty Implantation System.” Ex. K at 1.
`
`24. Exactech markets the Accused System relating to its Ankle
`
`Replacement Solutions as its Vantage® Total Ankle System and Vantage® Ankle
`
`PSI, part of its Active Intelligence® initiative. See e.g. Exs. L, Q.
`
`
`Ex. M at 3. The Accused System includes 3D-printed tibia and talar cutting guides
`
`and the associated ankle implants. Ex. M at 3-4.
`
`25. Exactech markets its Vantage® Ankle PSI 3D-printed tibia and talar
`
`cutting guides as “designed for patients’ unique anatomies” and stating that they
`
`8
`
`
`
`Case 8:21-cv-01348-KKM-TGW Document 1 Filed 06/03/21 Page 9 of 22 PageID 9
`
`“allow surgeons to pre-plan, are part of Exactech’s Active Intelligence® initiative
`
`and are used exclusively with the Vantage Total Ankle System.” Ex. L at 2.
`
`
`
`Id. The “cutting guides are created from patients’ CT scans and delivered in
`
`approximately two weeks. The cutting slots on the instrumentation feature a
`
`rippled surface to allow water to flow through to keep the bone cool during
`
`surgery. In addition, the instrumentation features soft tissue offsets, which are
`
`designed to allow the surgeon to remove less soft tissue.” Ex. M at 3-4.
`
`26. On information and belief, Exactech is infringing the Asserted Patents
`
`by making, using, providing, offering to sell, importing, and selling (directly or
`
`through intermediaries) the Accused System in this District and elsewhere in the
`
`9
`
`
`
`Case 8:21-cv-01348-KKM-TGW Document 1 Filed 06/03/21 Page 10 of 22 PageID 10
`
`United States, and by contributing to the infringement of, or inducing others to
`
`infringe the Asserted Patents.
`
`FIRST CLAIM FOR RELIEF
`
`(Infringement of the ’304 Patent)
`27. Conformis realleges paragraphs 1–26 above as if fully set forth herein.
`
`28. The ’304 Patent is a valid, enforceable patent that was duly issued by
`
`the USPTO on June 11, 2013. Ex. A.
`
`29. Conformis is the assignee of the ’304 Patent with ownership of all
`
`substantial rights in the ’304 Patent, including the right to exclude others and to
`
`enforce, sue, and recover damages for past and future infringements.
`
`30. Exactech has directly infringed, and continues to directly infringe, at
`
`least claim 1 of the ’304 Patent in violation of 35 U.S.C. § 271(a) by, for example
`
`and without limitation, making, using, offering to sell, selling, and/or importing in
`
`and into the United States the Accused System.
`
`31. Claim 1 of the ’304 Patent claims:
`
`A surgical instrument for use in surgically repairing a joint of a patient, the
`surgical instrument comprising:
`
` a
`
` mold having an internal surface that includes joint information
`derived from image data of the joint of the patient; and
`
`two or more guide holes, each configured to guide a surgical pin,
`wherein at least one of the two or more guide holes has a position
`based on anatomical information of the joint of the patient to facilitate
`
`10
`
`
`
`Case 8:21-cv-01348-KKM-TGW Document 1 Filed 06/03/21 Page 11 of 22 PageID 11
`
`the placement of an articular repair system when the internal surface
`of the mold is aligned with the joint of the patient,
`wherein the articular repair system has a predetermined rotation angle
`and
`wherein the position is based on the predetermined rotation angle.
`
`32. Exactech’s Accused System meets each of the above limitations.
`
`33. A more detailed analysis of Exactech’s infringement of the ’304
`
`Patent can be found in Exhibit F, which is incorporated in its entirety as if set forth
`
`herein.
`
`34. Exactech has actively induced others to infringe at least claim 1 of the
`
`’304 Patent in violation of 35 U.S.C. § 271(b) by instructing others to make, use,
`
`sell, offer to sell, and import into the United States the Accused System.
`
`35. Exactech has also contributed, and continues to contribute, to its
`
`customers’ and end users’ direct infringement of the ’304 Patent in violation of 35
`
`U.S.C. § 271(c) by offering for sale and providing the Accused System to end-
`
`users. The Accused System is specially made using joint information derived from
`
`image data of an individual patient’s joint. Such individualized surgical
`
`instruments are not staple articles of commerce and are not suitable for any
`
`substantial non-infringing use. Exactech’s use infringes at least claim 1 of the ’304
`
`Patent.
`
`11
`
`
`
`Case 8:21-cv-01348-KKM-TGW Document 1 Filed 06/03/21 Page 12 of 22 PageID 12
`
`36. Conformis has suffered economic harm because of Exactech’s
`
`infringing activities in an amount to be proven at trial, but in no case less than a
`
`reasonably royalty.
`
`37. Exactech has caused, and unless restrained and enjoined, will continue
`
`to cause, irreparable injury and damage to Conformis for which there is no
`
`adequate remedy at law. Unless enjoined by this Court, Exactech will continue to
`
`infringe the ’304 Patent.
`
`SECOND CLAIM FOR RELIEF
`
`(Infringement of the ’482 Patent)
`38. Conformis realleges paragraphs 1–37 above as if fully set forth herein.
`
`39. The ’482 Patent is a valid, enforceable patent that was duly issued by
`
`the USPTO on March 29, 2016. Ex. B.
`
`40. Conformis is the assignee of the ’482 Patent with ownership of all
`
`substantial rights in the ’482 Patent, including the right to exclude others and to
`
`enforce, sue, and recover damages for past and future infringements.
`
`41. Exactech has directly infringed, and continues to directly infringe, at
`
`least claim 1 of the ’482 Patent in violation of 35 U.S.C. § 271(a) by, for example
`
`and without limitation, making, using, offering to sell, selling, and/or importing in
`
`and into the United States the Accused System.
`
`42. Claim 1 of the ’482 Patent claims:
`
`12
`
`
`
`Case 8:21-cv-01348-KKM-TGW Document 1 Filed 06/03/21 Page 13 of 22 PageID 13
`
`A joint arthroplasty system for repairing a diseased or damaged joint of a
`patient[]comprising:
`an implant; and
`a patient-specific surgical instrument configured to facilitate the
`placement of the implant into the diseased or damaged joint, the
`instrument comprising:
`a patient-specific surface for engaging a corresponding portion
`of the diseased or damaged joint, the patient-specific surface
`including cartilage information derived from image data of the
`diseased or damaged joint,
`wherein the corresponding portion of the diseased or damaged
`joint includes an osteophyte,
`wherein the patient-specific surface references the osteophyte
`when the patient-specific surface is engaged and aligned with
`the corresponding portion of the diseased or damaged joint; and
`a guide sized and shaped to accommodate a surgical tool,
`wherein the guide has a position and orientation relative to the
`patient-specific surface to provide a predetermined path for the
`surgical tool.
`43. Exactech’s Accused System meets each of the above limitations.
`
`44. A more detailed analysis of Exactech’s infringement of the ’482
`
`Patent can be found in Exhibit G, which is incorporated in its entirety as if set forth
`
`herein.
`
`45. Exactech has actively induced others to infringe at least claim 1 of the
`
`’482 Patent in violation of 35 U.S.C. § 271(b) by instructing others to make, use,
`
`sell, offer to sell, and import into the United States the Accused System.
`
`13
`
`
`
`Case 8:21-cv-01348-KKM-TGW Document 1 Filed 06/03/21 Page 14 of 22 PageID 14
`
`46. Exactech has also contributed, and continues to contribute, to its
`
`customers’ and end users’ direct infringement of the ’482 Patent in violation of 35
`
`U.S.C. § 271(c) by offering for sale and providing the Accused System to end-
`
`users. The Accused System are specially made using joint information derived
`
`from image data of an individual patient’s joint. Such individualized surgical
`
`instruments are not staple articles of commerce and are not suitable for any
`
`substantial non-infringing use. Exactech’s use infringes at least claim 1 of the ’482
`
`Patent.
`
`47. Conformis has suffered economic harm because of Exactech’s
`
`infringing activities in an amount to be proven at trial, but in no case less than a
`
`reasonably royalty.
`
`48. Exactech has caused, and unless restrained and enjoined, will continue
`
`to cause, irreparable injury and damage to Conformis for which there is no
`
`adequate remedy at law. Unless enjoined by this Court, Exactech will continue to
`
`infringe the ’482 Patent.
`
`THIRD CLAIM FOR RELIEF
`
`(Infringement of the ’026 Patent)
`49. Conformis realleges paragraphs 1–48 above as if fully set forth herein.
`
`50. The ’026 Patent is a valid, enforceable patent that was duly issued by
`
`the USPTO on January 7, 2014. Ex. C.
`
`14
`
`
`
`Case 8:21-cv-01348-KKM-TGW Document 1 Filed 06/03/21 Page 15 of 22 PageID 15
`
`51. Conformis is the assignee of the ’026 Patent with ownership of all
`
`substantial rights in the ’026 Patent, including the right to exclude others and to
`
`enforce, sue, and recover damages for past and future infringements.
`
`52. Exactech has directly infringed, and continues to directly infringe, at
`
`least claim 24 of the ’026 Patent in violation of 35 U.S.C. § 271(a) and/or (g) by,
`
`for example and without limitation, making, using, offering to sell, selling, and/or
`
`importing in and into the United States the Accused System.
`
`53. Claim 24 of the ’026 Patent claims:
`
`A method of making a surgical tool, the method comprising:
`obtaining image data associated with at least a portion of a joint;
`deriving joint surface information from the image data;
`determining at least a portion of the joint surface to be engaged by a
`contact surface;
`determining an anatomical structure to be disengaged from a
`corresponding anatomical relief surface, and
`providing a surgical tool that includes a guide, the contact surface and
`the anatomical relief surface, the contact surface for engaging at least
`a portion of the joint surface, the anatomical relief surface being
`substantially disengaged from the anatomical structure when the
`contact surface is engaged with the at least a portion of the joint
`surface, the guide being configured to direct movement of a surgical
`instrument.
`
`
`54. Exactech’s Accused System meets each of the above limitations
`
`and/or are made by processes that meet each of the above limitations.
`
`15
`
`
`
`Case 8:21-cv-01348-KKM-TGW Document 1 Filed 06/03/21 Page 16 of 22 PageID 16
`
`55. A more detailed analysis of Exactech’s infringement of the ’026
`
`Patent can be found in Exhibit H, which is incorporated in its entirety as if set forth
`
`herein.
`
`56. Exactech has actively induced others to infringe at least claim 24 of
`
`the ’026 Patent in violation of 35 U.S.C. § 271(b) by instructing others to make,
`
`use, sell, offer to sell, and import into the United States the Accused System.
`
`57. Exactech has also contributed, and continues to contribute, to its
`
`customers’ and end users’ direct infringement of the ’026 Patent in violation of 35
`
`U.S.C. § 271(c) by offering for sale and providing the Accused System to end-
`
`users. The Accused System are specially made using joint information derived
`
`from image data of an individual patient’s joint. Such individualized surgical
`
`instruments are not staple articles of commerce and are not suitable for any
`
`substantial non-infringing use. Exactech’s use infringes at least claim 24 of the
`
`’026 Patent.
`
`58. Conformis has suffered economic harm because of Exactech’s
`
`infringing activities in an amount to be proven at trial, but in no case less than a
`
`reasonably royalty.
`
`59. Exactech has caused, and unless restrained and enjoined, will continue
`
`to cause, irreparable injury and damage to Conformis for which there is no
`
`adequate remedy at law. Unless enjoined by this Court, Exactech will continue to
`
`infringe the ’026 Patent.
`
`16
`
`
`
`Case 8:21-cv-01348-KKM-TGW Document 1 Filed 06/03/21 Page 17 of 22 PageID 17
`
`FOURTH CLAIM FOR RELIEF
`
`(Infringement of the ’780 Patent)
`60. Conformis realleges paragraphs 1–59 above as if fully set forth herein.
`
`61. The ’780 Patent is a valid, enforceable patent that was duly issued by
`
`the USPTO on May 3, 2016. Ex. D.
`
`62. Conformis is the assignee of the ’780 Patent with ownership of all
`
`substantial rights in the ’780 Patent, including the right to exclude others and to
`
`enforce, sue, and recover damages for past and future infringements.
`
`63. Exactech has directly infringed, and continues to directly infringe, at
`
`least claim 1 of the ’780 Patent in violation of 35 U.S.C. § 271(a) by, for example
`
`and without limitation, making, using, offering to sell, selling, and/or importing in
`
`and into the United States the Accused System.
`
`64. Claim 1 of the ’780 Patent claims:
`
`A system for joint arthroplasty for repairing a joint of a patient, the system
`comprising:
`a first template, the first template including:
`a contact surface for engaging a first articular surface of the
`joint of the patient, the contact surface including shape
`information derived from electronic image data of at least a
`portion of the first articular surface;
`at least a relieved portion of the contact surface further
`including an anatomical relief configured such that when the
`contact surface engages the first articular surface, the relieved
`portion does not engage an anatomical structure of the first
`articular surface; and
`
`17
`
`
`
`Case 8:21-cv-01348-KKM-TGW Document 1 Filed 06/03/21 Page 18 of 22 PageID 18
`
`at least one guide for directing movement of a surgical
`instrument; and
`wherein the guide has a predetermined orientation relative to one of
`an anatomical and a biomechanical axis associated with the joint of
`the patient.
`
`
`65. Exactech’s Accused System meets each of the above limitations.
`
`66. A more detailed analysis of Exactech’s infringement of the ’780
`
`Patent can be found in Exhibit I, which is incorporated in its entirety as if set forth
`
`herein.
`
`67. Exactech has actively induced others to infringe at least claim 1 of the
`
`’780 Patent in violation of 35 U.S.C. § 271(b) by instructing others to make, use,
`
`sell, offer to sell, and import into the United States the Accused System.
`
`68. Exactech has also contributed, and continues to contribute, to its
`
`customers’ and end users’ direct infringement of the ’780 Patent in violation of 35
`
`U.S.C. § 271(c) by offering for sale and providing the Accused System to end-
`
`users. The Accused System are specially made using joint information derived
`
`from image data of an individual patient’s joint. Such individualized surgical
`
`instruments are not staple articles of commerce and are not suitable for any
`
`substantial non-infringing use. Exactech’s use infringes at least claim 1 of the ’780
`
`Patent.
`
`18
`
`
`
`Case 8:21-cv-01348-KKM-TGW Document 1 Filed 06/03/21 Page 19 of 22 PageID 19
`
`69. Conformis has suffered economic harm because of Exactech’s
`
`infringing activities in an amount to be proven at trial, but in no case less than a
`
`reasonably royalty.
`
`70. Exactech has caused, and unless restrained and enjoined, will continue
`
`to cause, irreparable injury and damage to Conformis for which there is no
`
`adequate remedy at law. Unless enjoined by this Court, Exactech will continue to
`
`infringe the ’780 Patent.
`
`FIFTH CLAIM FOR RELIEF
`
`(Infringement of the ’161 Patent)
`71. Conformis realleges paragraphs 1–70 above as if fully set forth herein.
`
`72. The ’161 Patent is a valid, enforceable patent that was duly issued by
`
`the USPTO on November 17, 2015. Ex. E.
`
`73. Conformis is the assignee of the ’161 Patent with ownership of all
`
`substantial rights in the ’161 Patent, including the right to exclude others and to
`
`enforce, sue, and recover damages for past and future infringements.
`
`74. Exactech has directly infringed, and continues to directly infringe, at
`
`least claim 1 of the ’161 Patent in violation of 35 U.S.C. § 271(a) by, for example
`
`and without limitation, making, using, offering to sell, selling, and/or importing in
`
`and into the United States the Accused System.
`
`75. Claim 1 of the ’161 Patent claims:
`
`19
`
`
`
`Case 8:21-cv-01348-KKM-TGW Document 1 Filed 06/03/21 Page 20 of 22 PageID 20
`
`A surgical system including an articular repair system and a surgical
`instrument for use in surgically repairing a joint of a patient, the surgical
`instrument comprising:
`a mold having an internal surface that includes joint information
`derived from image data of the joint of the patient; and two or more
`guide holes, each configured to guide a surgical pin,
`wherein at least one of the two or more guide holes has a position
`and/or orientation based on anatomical information of the joint of the
`patient to facilitate the placement of the articular repair system when
`the internal surface of the mold is aligned with the joint of the patient,
`wherein the articular repair system has a predetermined rotation angle and
`wherein the position and/or orientation is based on the predetermined
`rotation angle.
`
`76. Exactech’s Accused System meets each of the above limitations.
`
`77. A more detailed analysis of Exactech’s infringement of the ’161
`
`Patent can be found in Exhibit J, which is incorporated in its entirety as if set forth
`
`herein.
`
`78. Exactech has actively induced others to infringe at least claim 1 of the
`
`’161 Patent in violation of 35 U.S.C. § 271(b) by instructing others to make, use,
`
`sell, offer to sell, and import into the United States the Accused System.
`
`79. Exactech has also contributed, and continues to contribute, to its
`
`customers’ and end users’ direct infringement of the ’161 Patent in violation of 35
`
`U.S.C. § 271(c) by offering for sale and providing the Accused System to end-
`
`users. The Accused System are specially made using joint information derived
`
`from image data of an individual patient’s joint. Such individualized surgical
`
`20
`
`
`
`Case 8:21-cv-01348-KKM-TGW Document 1 Filed 06/03/21 Page 21 of 22 PageID 21
`
`instruments are not staple articles of commerce and are not suitable for any
`
`substantial non-infringing use. Exactech’s use infringes at least claim 1 of the ’161
`
`Patent.
`
`80. Conformis has suffered economic harm because of Exactech’s
`
`infringing activities in an amount to be proven at trial, but in no case less than a
`
`reasonably royalty.
`
`81. Exactech has caused, and unless restrained and enjoined, will continue
`
`to cause, irreparable injury and damage to Conformis for which there is no
`
`adequate remedy at law. Unless enjoined by this Court, Exactech will continue to
`
`infringe the ’161 Patent.
`
`V.
`
`PRAYER FOR RELIEF
`
`WHEREFORE, Conformis requests entry of judgment in its favor and
`
`against Exactech as follows:
`
`1.
`
`Entry of judgment holding Exactech liable for infringement of the
`
`Asserted Patents;
`
`2.
`
`An order permanently enjoining Exactech, its officers, agents,
`
`servants, employees, attorneys and affiliated companies, its assigns and successors
`
`in interest, and those persons in active concert or participation with it, from
`
`continued acts of infringement of the Asserted Patents;
`
`3.
`
`An order awarding Conformis statutory damages and damages
`
`according to proof resulting from Exactech’s past, current, and future infringement
`21
`
`
`
`Case 8:21-cv-01348-KKM-TGW Document 1 Filed 06/03/21 Page 22 of 22 PageID 22
`
`of the Asserted Patents, together with prejudgment and post-judgment interest;
`
`4.
`
`A declaration that this case is exceptional under 35 U.S.C. § 285, and
`
`an award of Conformis’s reasonable attorneys’ fees;
`
`5.
`
`Any and all other legal or equitable relief as may be available under
`
`law and which the Court may deem proper.
`
`VI. JURY DEMAND
`
`Conformis hereby demands trial by jury in this action on all issues so triable.
`
`Dated: June 3, 2021.
`
`Respectfully submitted,
`JOHN R. EMERSON, ESQUIRE
`
`
`/s/ John N. Muratides
`JOHN N. MURATIDES, ESQUIRE
`russ.emerson@haynesboone.com
`Florida Bar No. 332615
`Lead Counsel
`STEPHANIE N. SIVINSKI, ESQUIRE
`jmuratides@stearnsweaver.com
`lwade@stearnsweaver.com
`stephanie.sivinski@haynesboone.com
`STEARNS WEAVER MILLER WEISSLER
`HAYNES AND BOONE, LLP
`ALHADEFF & SITTERSON, P.A.
`2323 Victory Avenue, Suite 700
`401 E. Jackson Street, Suite 2100 (33602)
`Dallas, Texas 75219
`Post Office Box 3299
`Tel. (214) 651-5000
`Tampa, Florida 33601
`
`Tel. (813) 223-4800/Fax (813) 222-5089
`Admission Pro Hac Vice pending
`
`
`JASON T. LAO, ESQUIRE
`
`jason.lao@haynesboone.com
`LINFENG YANG, ESQUIRE
`ANDREA LEVENSON, ESQUIRE
`lin.yang@haynesboone.com
`andrea.levenson@haynesboone.com
`HAYNES AND BOONE, LLP
`HAYNES AND BOONE, LLP
`201 Spear Street, Suite 1750
`600 Anton Blvd., Suite 700
`San Francisco, CA 94105
`Costa Mesa, CA 92626
`(415) 293-8900
`(949) 202-3000
`Admission Pro Hac Vice pending
`
`Admission Pro Hac Vice pending
`
`COUNSEL FOR PLAINTIFF CONFORMIS, INC.
`
`
`
`
`
`22
`
`